Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis was written by Khurana, Arushi;Dalland, Joanna C.;Young, Jason R.;Inwards, David J.;Paludo, Jonas. And the article was included in American Journal of Hematology in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:
The ZUMA-2 trial, however, excluded patients with a possible requirement for urgent therapy due to ongoing or impending oncol. emergency (eg, tumor mass effect, tumor lysis syndrome), involvement of the central nervous system and required patients to be exposed to a Bruton tyrosine kinase (BTK) inhibitor. Interim PET/CT after three cycles of bendamustine and rituximab, showed a significant improvement in lymphadenopathy and skeletal lesions, however, with new lesions in the nasopharynx and right chest wall. The patient underwent brexu-cel therapy after lymphodepletion chemo but his course was complicated by cytokine release syndrome (CRS) on day +1 with a peak grade of one based on the ASTCT 2019 grading. This is the first report of a brexu-cel for MCL-associated NL and blastoid variant with complete remission at day +60 without added neurotoxicity. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. COA of Formula: C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem